TrialJournal of acquired immune deficiency syndromes (1999)2010

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Timothy J Wilkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.